Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026)
Zymeworks (ZYME) posted Other Non-Current Liabilities of $278000.0 for Q1 2026, little changed sequentially from $278000.0 in Q4 2025, and down 67.52% YoY from $856000.0 in Q1 2025.
Analysis
Zymeworks (ZYME) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks has reported Other Non-Current Liabilities for 6 years, with the latest figure at $278000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 67.52% year-over-year to $278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278000.0 (down 67.52% YoY) and the FY2025 annual result came in at $278000.0, down 69.88% from the prior year.
- Other Non-Current Liabilities held at $278000.0 in Q1 2026 per ZYME's latest filing, from $278000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $3.6 million in Q2 2023 and troughed at $278000.0 in Q3 2025.
- A 5-year average of $1.4 million and a median of $929000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities sank 90.01% in 2023, then jumped 217.06% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $1.6 million in 2022, then rose by 3.59% to $1.7 million in 2023, then plunged by 45.74% to $923000.0 in 2024, then sank by 69.88% to $278000.0 in 2025, then changed by 0.0% to $278000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $278000.0, $278000.0, and $278000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 278,000.00 |
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 828,000.00 |
| Mar 31, 2025 | 856,000.00 |
| Dec 31, 2024 | 923,000.00 |
| Sep 30, 2024 | 929,000.00 |
| Jun 30, 2024 | 1.23 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.86 Mn |
| Jun 30, 2023 | 3.60 Mn |
| Mar 31, 2023 | 3.60 Mn |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 2.93 Mn |
| Dec 31, 2021 | 7.75 Mn |